Clinical trial NCT05482672: GetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and Depression
Official title: GetHealthy-OA: A Biopsychosocial Treatment Approach to Improve Pain and Function for Patients With Comorbid Knee Osteoarthritis, Obesity, and Depression
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
PHASE3
Conditions: Knee Osteoarthritis
Obese
Depression
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
Collaborators: name: Massachusetts General Hospital
First posted: 2022-08-01
Enrollment: 0
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators have previously identified knee osteoarthritis patients with the combination of depression and an unhealthy weight may be an increased risk of more rapid joint degeneration and worsening pain. The GetHealthy-OA program combines a mind-body program with the oral supplement fisetin to potentially reduce the risk for this population by treating psychosocial, mechanical, and inflammatory mechanisms of knee osteoarthritis. This randomized clinical trial will compare the GetHealthy-OA program to minimally-enhanced usual care plus an oral placebo.

Detailed description: The study will employ a double-blind, randomized, placebo-controlled clinical trial to compare the the multimodal GetHealthy-OA program versus placebo. As part of this clinical trial, 120 patients will be randomized to 1 of 2 groups: The GetHealthy-OA program that combines a mind-body program with oral fisetin versus a control group treated with an oral placebo and minimally-enhanced usual care (MEUC). The GetHealthy-OA group will participate in the 6-week the mind-body program and will take oral fisetin for 2 consecutive days (day 1 and 2), a 28-day wash-out period, and then another 2-day course (days 31 and 32). The MEUC group will be given a health education handout at the date of baseline testing and will take an oral placebo for 2 consecutive days (day 1 and 2) and then again 28 days later (days 29 and 30). To determine if immediate improvements are realized and whether gains are sustained after the completing the program, participants will be assessed at baseline, 6 weeks, 3 months, and 6 months.

The GetHealthy-OA mind-body program is a live-video, group program delivered via secure telehealth with mind-body skills to reduce pain and increase physical activity to promote optimal joint loading. The on-line program will be delivered remotely by a psychologist based at Massachusetts General Hospital via Zoom and we will assess symptoms and monitor any technical difficulties. The program consist of 6 sessions that will last about 45 minutes. The sessions are done on your smartphone or computer, and will include a group of 4 to 5 other people with knee arthritis who are also taking part in the study with you at the same time. The GetHealthy-OA group will participate in the 6-week the mind-body program and will take oral fisetin for 2 consecutive days (day 1 and 2), a 28-day wash-out period, and then another 2-day course (days 31 and 32).

The MEUC group will be given a health education booklet at the date of baseline testing and will take an oral placebo (corn starch) for 2 consecutive days (day 1 and 2) and then again 28 days later (days 29 and 30). The booklet will contain brief summarized information that reflects the active intervention topics including the trajectory of pain and recovery for those with knee osteoarthritis, the role of relaxation strategies to manage pain, and the importance of returning to engagement in activities of daily living. The MEUC will be given an oral placebo (corn starch) that is identical to the fisetin capsules with the same dosing regimen as the GetHealthy-OA group. Similar to participants in GetHealthy-OA group, participants in this group will receive usual medical care as determined by the medical team. Usual care involves meetings with physicians, medical staff, and physical therapy. Usual care is identical in intervention and control groups.

Eligibility criteria: Inclusion Criteria:

* Mild to moderate knee osteoarthritis (Kellgren/Lawrence Grade II or III)
* Obesity (Body Mass Index \> 30 kg/m2)
* History of concurrent psychotropics for \< 2 weeks prior to initiation of treatment or on stable doses for \> 6 weeks
* Access to an internet-enabled computer/smart phone
* Willingness to comply with the study protocol and assessments
* Cleared by a medical doctor to participate

Exclusion Criteria:

* Rheumatoid arthritis
* History of cancer within 5 years of screening; unable to walk/wheelchair-bound
* Prior surgical fixation of a femur or tibia fracture
* Taking high doses of opioid pain medication (\>50 milligrams of morphine equivalent per day)
* Diagnosis of a medical illness expected to worsen in the next 6 months (e.g., malignancy)
* Active suicidal ideation or past-year psychiatric hospitalization; non-English speaking
* Lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder
* Current substance abuse or dependence (or a history within the past 6 months)
* Practice of yoga/meditation, or other mind body techniques once per week \> 45 min within the last 3 months
* Engagement in regular moderate or vigorous physical exercise for \>30 min daily
* Reduced or altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, or brain injury
* Females who are nursing, pregnant or planning to become pregnant during the duration of study drug dosing
* Females or males who do not wish to abstain from sex or use contraceptive protection during study drug dosing and for 2 weeks after the last dose

  o Those not willing to use 2 of the following effective forms of contraception: sterilization surgery, intrauterine device (IUD), implantable rod, contraceptive shot/injection, oral contraceptives, patch, vaginal ring, diaphragm with spermicide, sponge with spermicide, cervical cap with spermicide, and/or a male or female condom
* Subjects who do not have the capacity to consent themselves
* Subjects who are unable to tolerate oral medication
* Subjects having previously undergone any of the following treatments in the stated time window.

  * Surgery on the Study Knee in the past 6 months
  * Partial or complete joint replacement in the study knee. Partial or complete joint replacement in the contralateral knee is acceptable as long as the surgery was performed at least 6 months prior to enrollment and the operative knee is asymptomatic
  * Patients who have undergone arthroscopic surgery (including microfracture and meniscectomy) on the Study Knee in the last 2 years prior to the Screening visit or are anticipated to have arthroscopic surgery on either knee at any time during the study period
  * Currently taking Losartan
  * Currently taking Warfarin or related anticoagulants
  * Senolytic agents taken within the past 6 months and are not willing to discontinue these medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax
  * Drugs that induce significant cellular stress and are not willing to discontinue these medications through the duration of the study, including alkylating agents, anthracyclines, platins, other chemotherapy drugs
  * Medications that are sensitive substrates or substrates with a narrow therapeutic range for cytochrome P450 family 1 subfamily A member 2 (CYP1A2), cytochrome P450 family 2 subfamily C member 8 (CYP2C8), cytochrome P450 family 2 subfamily C member 9 (CYP2C9), cytochrome P450 family 2 subfamily C member 19 (CYP2C19), cytochrome P450 family 2 subfamily D member 6 (CYP2D6), cytochrome P450 family 3 subfamily A member 4 (CYP3A4), Organic Anion Transporting Polypeptide 1B1 (OATP1B1) or strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4; e.g. cyclosporine, tacrolimus or sirolimus)
  * Subjects taking the following other drugs if they cannot be held (per the Medical Director Austin Stone, MD, PhD) for at least 2 days before and during administration of Fisetin: cyclosporine, tacrolimus, repaglinide, and bosentan
  * Significant liver disease (i.e. greater than or equal to 2x the upper limit of normal bilirubin levels) or as in the opinion of the Medical Director
  * Significant renal disease (estimated glomerular filtration rate (eGFR) of \<60 ml/min/1.73m2) or as in the opinion of the Medical Director
  * History of other formally diagnosed joint diseases including osteonecrosis, acromegaly, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease, Cushing's syndrome, Stickler's syndrome, joint infection, hemophilia, hemochromatosis, or neuropathic arthropathy of any cause
  * Patients with type 1 or 2 diabetes (Hemoglobin A1c (HbA1c) \> 6.5%) and/or taking medications that affect insulin levels, including: Metformin (within the last week), Glucocorticoids (within the last month), Acarbose (within the last week)

Primary outcomes:
measure: Change in Western Ontario and MacMaster Universities Osteoarthritis Index (WOMAC)
timeFrame: Change between Baseline and 3 months
measure: Change in Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference
timeFrame: Change between Baseline and 3 months
measure: Change in Average Daily Step Count
timeFrame: Change between Baseline and 3 months
Secondary outcomes:
measure: Change in serum Interleukin-17 (IL-17)
timeFrame: Change between Baseline and 6-weeks, 3-months, and 6-months
measure: Change in serum IL-4
timeFrame: Change between Baseline and 6-weeks, 3-months, and 6-months
measure: Change in urinary C-terminal crosslinked telopeptide type II collagen (CTX-II)
timeFrame: Change between Baseline and 6-weeks, 3-months, and 6-months
measure: Change in serum Chondroitin Sulfate epitope 846 (CS846)
timeFrame: Change between Baseline and 6-weeks, 3-months, and 6-months
measure: Change in Pain Numerical Rating Scale
timeFrame: Change between Baseline and 6-weeks, 3-months, and 6-months
measure: Change in Walking Speed
timeFrame: Change between Baseline and 6-weeks, 3-months, and 6-months
measure: Arthritis Self-Efficacy Scale (ASES)
timeFrame: Change between Baseline and 6-weeks, 3-months, and 6-months
measure: PROMIS Depression
timeFrame: Change between Baseline and 6-weeks, 3-months, and 6-months
measure: PROMIS Anxiety
timeFrame: Change between Baseline and 6-weeks, 3-months, and 6-months
measure: Pain Catastrophizing Scale (PCS)
timeFrame: Change between Baseline and 6-weeks, 3-months, and 6-months
measure: RU SATED
timeFrame: Change between Baseline and 6-weeks, 3-months, and 6-months
Other outcomes:
Locations:
city: Lexington
country: United States
facility: UK Healthcare at Turfland
state: Kentucky
city: Lexington
country: United States
facility: UK HealthCare Joint Reconstruction and Replacement
state: Kentucky
Study officials:
affiliation: University of Kentucky
name: Cale Jacobs, PhD
role: PRINCIPAL_INVESTIGATOR
References: